LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

587.45 8.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

533.86

Max

590.71

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
EPS	-4.956
Winstmarge	-39.75
Werknemers	528
EBITDA	-75M -114M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+6.94% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.5B 13B
Vorige openingsprijs	579.19
Vorige sluitingsprijs	587.45

Nieuwssentiment

By Acuity

50%

167 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 dec 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec 2025, 23:51 UTC

Winsten

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec 2025, 23:39 UTC

Belangrijke Marktbewegers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec 2025, 21:40 UTC

Winsten

Nike Sales Tick Up, But China Weakness Persists

18 dec 2025, 23:45 UTC

Marktinformatie

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec 2025, 23:37 UTC

Marktinformatie

Winsten

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec 2025, 23:36 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec 2025, 23:00 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec 2025, 22:58 UTC

Acquisities, Fusies, Overnames

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec 2025, 22:56 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec 2025, 22:55 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:59 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

18 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 dec 2025, 21:35 UTC

Winsten

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec 2025, 21:31 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev Down 17% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q EPS 53c >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Apparel Rev $3.91B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Equipment Rev $550M >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q N Amer Rev $5.63B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Footwear Rev $7.66B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev $1.42B >NKE

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

6.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 584.09 USD 6.94%

Hoogste 670 USD

Laagste 523 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

167 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.